<code id='E3F301D2CC'></code><style id='E3F301D2CC'></style>
    • <acronym id='E3F301D2CC'></acronym>
      <center id='E3F301D2CC'><center id='E3F301D2CC'><tfoot id='E3F301D2CC'></tfoot></center><abbr id='E3F301D2CC'><dir id='E3F301D2CC'><tfoot id='E3F301D2CC'></tfoot><noframes id='E3F301D2CC'>

    • <optgroup id='E3F301D2CC'><strike id='E3F301D2CC'><sup id='E3F301D2CC'></sup></strike><code id='E3F301D2CC'></code></optgroup>
        1. <b id='E3F301D2CC'><label id='E3F301D2CC'><select id='E3F301D2CC'><dt id='E3F301D2CC'><span id='E3F301D2CC'></span></dt></select></label></b><u id='E3F301D2CC'></u>
          <i id='E3F301D2CC'><strike id='E3F301D2CC'><tt id='E3F301D2CC'><pre id='E3F301D2CC'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:141
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          RaDonda Vaught case: a double standard for nurses, physicians
          RaDonda Vaught case: a double standard for nurses, physicians

          RaDondaVaughtsitsinthecourtroomaheadofhersentencinginNashville,Tenn.,onFriday.NicoleHester/TheTennes

          read more
          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more

          PhRMA sues HHS over Medicare drug price negotiation

          PhRMAissuingtheBidenadministrationoveritsnewMedicaredrugpricenegotiationprogram.GraemeSloan/SipaUSAW